SERONO AND SYNTONIX TO PURSUE THE DEVELOPMENT OF A LONG-ACTING, INHALEABLE FSH THERAPY TO TREAT INFERTILITY

Serono and Syntonix Pharmaceuticals Inc. announced that they have entered into an agreement under which the companies will evaluate Syntonix' FSH:Fc SynFusion products for further development. Syntonix' SynFusion and Transceptor technologies may enable the development of a long-acting FSH therapy for the treatment of infertility that can be inhaled and dosed less frequently, instead of injected daily. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-18-2006/0004434183&EDATE=)